Allergan

Latest stories

1d
TheStreet.com
3 value stocks ready to outperform"It's growing in the Northeast as people shift from heating oil and coal to nat
3 value stocks ready to outperform
TheStreet.com / Posted yesterday
"It's growing in the Northeast as people shift from heating oil and coal to natural gas," said Forester. "Think of it as a growth utility because it is growing EBITDA by about 10% a year, has a 5.5% dividend and still has an attractive... Read more
1d
NJ Biz
BioNJ gala celebrates New Jersey's impact on the life sciences industryBioNJ held its ninth annual gala dinner last week and presented awards for key
BioNJ gala celebrates New Jersey's impact on the life sciences industry
NJ Biz / Posted yesterday
BioNJ held its ninth annual gala dinner last week and presented awards for key drug approvals and achievements in the life sciences industry. A least half of the drug approvals in 2015 were from the Garden State, CEO and President Debbie Hart told... Read more
1d
Business Wire
TransCelerate BioPharma Introduces New Subsidiary BioCelerate to Increase Efficiencies in Preclinical ResearchPHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma, Inc. announced today th
TransCelerate BioPharma Introduces New Subsidiary BioCelerate to Increase Efficiencies in Preclinical Research
Business Wire / Posted yesterday
PHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma, Inc. announced today that it is launching BioCelerate, a new subsidiary that aims to improve efficiencies in preclinical research. The six initial biopharmaceutical companies committed to... Read more
1d
Investopedia
Where Does Bill Ackman Keep His Money?Bill Ackman is the founder of activist hedge fund Pershing Square Capital Manag
Where Does Bill Ackman Keep His Money?
Investopedia / Posted yesterday
Bill Ackman is the founder of activist hedge fund Pershing Square Capital Management. The Harvard graduate has grown Pershing Square to around $19 billion in assets under management (AUM) as of 2015. Ackman and Pershing Square have been involved in... Read more
2d
San Antonio Express-News
Pfizer Gets Back to GrowthAfter years of struggling to offset crashing sales tied to the loss of patent p
Pfizer Gets Back to Growth
San Antonio Express-News / Posted 2 days ago
After years of struggling to offset crashing sales tied to the loss of patent protection on its megablockbuster drug Lipitor, Pfizer's management reports that the company's sales will finally stop falling, and start growing again this year. Will this... Read more
2d
Naked Capitalism
Tax Breaks for Big Pharma on Top of Unreasonable Price HikesBig Pharma has standard responses to this hostility. It claims that Turing and
Tax Breaks for Big Pharma on Top of Unreasonable Price Hikes
Naked Capitalism / Posted 2 days ago
Big Pharma has standard responses to this hostility. It claims that Turing and Valeant are bad actors, leaving the implication that all other companies are fabulous corporate citizens. Recently it began telling heart-warming stories about how the... Read more
4 related stories
3d
iol.co.za
Pfizer names new executivesNew York - Pfizer announced a new leadership structure for when it closes its $
Pfizer names new executives
iol.co.za / Posted 3 days ago
New York - Pfizer announced a new leadership structure for when it closes its $160-billion deal with Allergan, naming two Pfizer executives and an Allergan employee to run three different segments within the company’s two main businesses. Albert... Read more
4 related stories
3d
CNBC
Lightning Round: It's finally in the sweet spotIt's that time again! Jim Cramer rang the lightning round bell, which means he
Lightning Round: It's finally in the sweet spot
CNBC / Posted 3 days ago
It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed: Allergan: "Allergan has come down a lot. It's a charitable trust name, Jack Mohr and I have been saying look we... Read more
3d
FOX Business
Pfizer Outlines Post-Merger Management SlatePfizer Inc. on Monday unveiled its slate of executives who will run the combine
Pfizer Outlines Post-Merger Management Slate
FOX Business / Posted 3 days ago
Pfizer Inc. on Monday unveiled its slate of executives who will run the combined company after it closes its roughly $150 billion inversion deal to buy Allergan PLC. As previously announced, Allergan's chief executive, Brent Saunders, will become... Read more
4 related stories
3d
FOX Business
Pfizer Outlines Post-Merger Management SlatePfizer Inc. on Monday unveiled its slate of executives who will run the combine
Pfizer Outlines Post-Merger Management Slate
FOX Business / Posted 3 days ago
Pfizer Inc. on Monday unveiled its slate of executives who will run the combined company after it closes its roughly $150 billion inversion deal to buy Allergan PLC. As previously announced, Allergan's chief executive, Brent Saunders, will become... Read more
4 related stories
3d
Reuters
Pfizer unveils management line up for combined companyThe Pfizer logo is pictured on the company's World Headquarters building in the
Pfizer unveils management line up for combined company
Reuters / Posted 3 days ago
The Pfizer logo is pictured on the company's World Headquarters building in the Manhattan borough of New York November 23, 2015. Pfizer agreed in November to buy Botox-maker Allergan in a deal meant to slash Pfizer's tax rate as the tax-inversion... Read more
4 related stories
4d
The Sacramento Bee
An outrageous tax-skipping scamBurger King’s tax avoidance scheme was stomach turning. Pfizer’s gambit gave us
An outrageous tax-skipping scam
The Sacramento Bee / Posted 4 days ago
Burger King’s tax avoidance scheme was stomach turning. Pfizer’s gambit gave us a big headache. But this latest tax-skipping scam by Johnson Controls is enough to drive anyone bonkers, not just Bernie Sanders. The auto parts manufacturer announced... Read more
5d
MedCity News
Closing thoughts on the J.P. Morgan Healthcare ConferenceOur livers rested, our business cards sheathed – one more year of the J.P. Morg
Closing thoughts on the J.P. Morgan Healthcare Conference
MedCity News / Posted 5 days ago
Our livers rested, our business cards sheathed – one more year of the J.P. Morgan Healthcare Conference has come and gone. Given that the week was relatively quiet in terms of breaking news, the focus rested more solidly on trend analysis, moodiness... Read more
6d
Channel NewsAsia
Supernus beats Allergan over epilepsy drug patentsREUTERS: A federal judge on Friday said Allergan Plc's plan to sell a generic v
Supernus beats Allergan over epilepsy drug patents
Channel NewsAsia / Posted 6 days ago
REUTERS: A federal judge on Friday said Allergan Plc's plan to sell a generic version of a drug meant to treat epilepsy infringed patents belonging to Supernus Pharmaceuticals Inc. Supernus shares rose as much as 44 percent. In a 136-page decision,... Read more
6d
National Post
Story | Business Wire News Releases | News | Financial PostThe Canadian pharmaceutical market is the eighth largest in the world, accounti
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 6 days ago
The Canadian pharmaceutical market is the eighth largest in the world, accounting for about two percent of the world market by sales. Canada also has the fourth fastest growing pharmaceutical industry after China, the US and Spain and has shown a... Read more
6d
Morningstar
Pfizer's Pipeline Productivity Is ImprovingIn the quarter, growth from vaccine Prevnar 13 and recently launched drugs help
Pfizer's Pipeline Productivity Is Improving
Morningstar / Posted 6 days ago
In the quarter, growth from vaccine Prevnar 13 and recently launched drugs helped offset generic competition, leading to 5% year-over-year operational growth (excluding the Hospira acquisition). While the organic growth rate is likely to slow in 2016... Read more
7d
Yahoo News
Martin Shkreli could not stop laughing during his testimony to Congress Infamous former Turing CEO Martin Shkreli and Howard Schiller, the interim ch
Martin Shkreli could not stop laughing during his testimony to Congress
Yahoo News / Posted 7 days ago
Infamous former Turing CEO Martin Shkreli and Howard Schiller, the interim chief executive of the pharmaceutical company Valeant, just faced Congress. Legislators on Thursday... Read more
354 related stories
7d
National Post
Story | Business Wire News Releases | News | Financial PostKlick attracts leading healthcare marketing professionals with its consistent g
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 7 days ago
Klick attracts leading healthcare marketing professionals with its consistent growth, unique industry approach, and commitment to the ‘relentless pursuit of awesome’ TORONTO--(BUSINESS WIRE)--Klick Health today put an end to industry rumors and... Read more
7d
Business Insider
Martin Shkreli could not stop laughing during his testimony to CongressHoward Schiller, the interim chief executive of pharmaceutical company Valeant,
Martin Shkreli could not stop laughing during his testimony to Congress
Business Insider / Posted 7 days ago
Howard Schiller, the interim chief executive of pharmaceutical company Valeant, and infamous former Turing CEO Martin Shkreli just faced Congress. Legislators wanted them to answer for dramatic drug price increases that impact the lives of... Read more
8d
San Antonio Express-News
5 Stunning Numbers From Pfizer's Q4 Report That You May Have MissedIn case you missed it, one of the world's largest pharmaceutical companies, Pfi
5 Stunning Numbers From Pfizer's Q4 Report That You May Have Missed
San Antonio Express-News / Posted 8 days ago
In case you missed it, one of the world's largest pharmaceutical companies, Pfizer , reported its fourth-quarter results before the opening bell on Tuesday, and its headline figures painted a pretty impressive picture. Pfizer's Q4, by the numbers... Read more
9d
Canberra Times
Valeant Pharmaceuticals rout hammers drug stocksBill Ackman's investment firm Pershing Square Capital held a 5.7 per cent stake
Valeant Pharmaceuticals rout hammers drug stocks
Canberra Times / Posted 9 days ago
Bill Ackman's investment firm Pershing Square Capital held a 5.7 per cent stake in Valeant at the end of the second quarter. Photo: Scott Eells A $US20 billion selloff in Valeant Pharmaceuticals International spurred a battering in drug stocks seen... Read more
2 related stories
9d
The Age
Valeant Pharmaceuticals rout hammers drug stocksBill Ackman's investment firm Pershing Square Capital held a 5.7 per cent stake
Valeant Pharmaceuticals rout hammers drug stocks
The Age / Posted 9 days ago
Bill Ackman's investment firm Pershing Square Capital held a 5.7 per cent stake in Valeant at the end of the second quarter. Photo: Scott Eells A $US20 billion selloff in Valeant Pharmaceuticals International spurred a battering in drug stocks seen... Read more
2 related stories
9d
Sydney Morning Herald
Valeant Pharmaceuticals rout hammers drug stocksBill Ackman's investment firm Pershing Square Capital held a 5.7 per cent stake
Valeant Pharmaceuticals rout hammers drug stocks
Sydney Morning Herald / Posted 9 days ago
Bill Ackman's investment firm Pershing Square Capital held a 5.7 per cent stake in Valeant at the end of the second quarter. Photo: Scott Eells A $US20 billion selloff in Valeant Pharmaceuticals International spurred a battering in drug stocks seen... Read more
2 related stories
9d
TheStreet.com
4 "momentum triggers" that could give this biotech stock 64% growthThe development of orphan drugs is a booming niche and Teva has been muscling i
4 "momentum triggers" that could give this biotech stock 64% growth
TheStreet.com / Posted 9 days ago
The development of orphan drugs is a booming niche and Teva has been muscling in. The company is developing cancer drugs in orphan and other cancer indications for the treatment of patients who are failing to respond to existing conventional... Read more
9d
Morningstar
Pfizer Looks UndervaluedWe think the market is underestimating the pharma giant’s long-term earnings po
Pfizer Looks Undervalued
Morningstar / Posted 9 days ago
We think the market is underestimating the pharma giant’s long-term earnings potential. We are holding firm to our $38 fair value estimate following Pfizer’s steady fourth-quarter results that largely matched both our and consensus expectations. At... Read more
9d
Business Wire
FiscalNote raises $10 million Series C to further help organizations analyze government riskLeading the funding were financial technology firms Visionnaire Ventures and Gr
FiscalNote raises $10 million Series C to further help organizations analyze government risk
Business Wire / Posted 9 days ago
Leading the funding were financial technology firms Visionnaire Ventures and Green Visor Capital. Participating investors included New Enterprise Associates, co-founder and former CEO of Yahoo! Inc. Jerry Yang, Mark Cuban, 645 Ventures, Renren, Plug... Read more
9d
Lake Placid News
Pfizer earnings fall but tops Street 4Q forecastsNEW YORK (AP) — Pfizer Inc. reported that its fourth-quarter profit fell by hal
Pfizer earnings fall but tops Street 4Q forecasts
Lake Placid News / Posted 9 days ago
NEW YORK (AP) — Pfizer Inc. reported that its fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, yet the world's second-biggest drugmaker topped Wall Street expectations. The New York-based... Read more
21 related stories
9d
The Tampa Tribune
Pfizer earnings fall but tops Street 4Q forecastsPfizer Inc.'s fourth-quarter profit fell by half due to higher costs for produc
Pfizer earnings fall but tops Street 4Q forecasts
The Tampa Tribune / Posted 9 days ago
Pfizer Inc.'s fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, yet the world's second-biggest drugmaker managed to beat Wall Street expectations. The New York-based company's revenue rose by 7... Read more
21 related stories
9d
The Register NorthJersey.com
Pfizer earnings fall but tops Street 4Q forecastsPfizer Inc.'s fourth-quarter profit fell by half due to higher costs for produc
Pfizer earnings fall but tops Street 4Q forecasts
The Register NorthJersey.com / Posted 9 days ago
Pfizer Inc.'s fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, yet the world's second-biggest drugmaker managed to beat Wall Street expectations. The New York-based company's revenue rose by 7... Read more
21 related stories
9d
The Irish Times
Pfizer misses analysts’ estimates with resultsUS drugmaker Pfizer, which is in the process of buying Botox-maker Allergan for
Pfizer misses analysts’ estimates with results
The Irish Times / Posted 9 days ago
US drugmaker Pfizer, which is in the process of buying Botox-maker Allergan for $160 billion, forecast 2016 revenue and earnings below analysts’ estimates, citing generic competition and a strong dollar. The company said it expects reported revenue... Read more
21 related stories
9d
RTE News
Costs and strong dollar hits Pfizer's earningsPfizer reported a large drop in fourth-quarter earnings due to higher expenses
Costs and strong dollar hits Pfizer's earnings
RTE News / Posted 9 days ago
Pfizer reported a large drop in fourth-quarter earnings due to higher expenses and the strong dollar, but said it was on track to complete its takeover of Allergan. Earnings for the quarter ending 31 December were $613 million, a 50% drop compared... Read more
21 related stories
9d
Morningstar
Pfizer Beats Expectations, but Guidance DisappointsPfizer, which struck a $155 billion deal in November to combine with Allergan P
Pfizer Beats Expectations, but Guidance Disappoints
Morningstar / Posted 9 days ago
Pfizer, which struck a $155 billion deal in November to combine with Allergan PLC, said it expects to earn $2.20 to $2.30 a share this year, excluding special items. Analysts polled by Thomson Reuters had forecast $2.36 a share in earnings. The... Read more
21 related stories
9d
Your Hometown Lima Stations
Pfizer earnings fall but tops Street 4Q forecastsNEW YORK (AP) - Pfizer Inc. reported that its fourth-quarter profit fell by hal
Pfizer earnings fall but tops Street 4Q forecasts
Your Hometown Lima Stations / Posted 9 days ago
NEW YORK (AP) - Pfizer Inc. reported that its fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, yet the world's second-biggest drugmaker topped Wall Street expectations. The New York-based... Read more
21 related stories
9d
Channel NewsAsia
Pfizer forecasts 2016 revenue, earnings below estimatesREUTERS: U.S. drugmaker Pfizer Inc , which is in the process of buying Botox-ma
Pfizer forecasts 2016 revenue, earnings below estimates
Channel NewsAsia / Posted 9 days ago
REUTERS: U.S. drugmaker Pfizer Inc , which is in the process of buying Botox-maker Allergan Plc for US$160 billion, forecast 2016 revenue and earnings below analysts' estimates, citing generic competition and a strong dollar. The company said it... Read more
21 related stories
9d
Market Watch
Pfizer beats estimates, but guidance disappointsPfizer Inc. on Tuesday reported better-than-expected results for its fourth qua
Pfizer beats estimates, but guidance disappoints
Market Watch / Posted 9 days ago
Pfizer Inc. on Tuesday reported better-than-expected results for its fourth quarter thanks to last year's acquisition of Hospira Inc. and strong sales of new drugs, but the pharmaceutical giant offered soft guidance for 2016. Pfizer, which struck a... Read more
21 related stories
9d
FOX Business
Pfizer's 4Q Earnings Beat, Outlook MissesU.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan P
Pfizer's 4Q Earnings Beat, Outlook Misses
FOX Business / Posted 9 days ago
U.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan Plc for $160 billion, reported better-than-expected quarterly revenue, helped by demand for its pneumonia vaccine and its Hospira acquisition. The company, however,... Read more
21 related stories
9d
FOX Business
Pfizer Beats Profit Expectations, But Provides Downbeat OutlookPfizer Inc. reported on Tuesday fourth-quarter earnings of $613 million, or 10
Pfizer Beats Profit Expectations, But Provides Downbeat Outlook
FOX Business / Posted 9 days ago
Pfizer Inc. reported on Tuesday fourth-quarter earnings of $613 million, or 10 cents per share, compared with $1.228 billion, or 19 cents per share the same period a year ago. The latest results include three months of legacy Hospira global... Read more
21 related stories
9d
FOX Business
Pfizer's 4Q Earnings Beat, Outlook MissesU.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan P
Pfizer's 4Q Earnings Beat, Outlook Misses
FOX Business / Posted 9 days ago
U.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan Plc for $160 billion, reported better-than-expected quarterly revenue, helped by demand for its pneumonia vaccine and its Hospira acquisition. Continue Reading Below The... Read more
21 related stories
9d
FOX Business
Pfizer Beats Profit Expectations, But Provides Downbeat OutlookPfizer Inc. reported on Tuesday fourth-quarter earnings of $613 million, or 10
Pfizer Beats Profit Expectations, But Provides Downbeat Outlook
FOX Business / Posted 9 days ago
Pfizer Inc. reported on Tuesday fourth-quarter earnings of $613 million, or 10 cents per share, compared with $1.228 billion, or 19 cents per share the same period a year ago. The latest results include three months of legacy Hospira global... Read more
21 related stories
9d
Channel NewsAsia
Pfizer revenue beats estimates, helped by pneumonia vaccine salesREUTERS: U.S. drugmaker Pfizer Inc , which is in the process of buying Botox-ma
Pfizer revenue beats estimates, helped by pneumonia vaccine sales
Channel NewsAsia / Posted 9 days ago
REUTERS: U.S. drugmaker Pfizer Inc , which is in the process of buying Botox-maker Allergan Plc for US$160 billion, reported better-than-expected quarterly revenue, helped by demand for its pneumonia vaccine and its Hospira acquisition. The company,... Read more
21 related stories
9d
Market Watch
Pfizer beats estimates but guidance disappointsPfizer Inc. on Tuesday reported better-than-expected results for its fourth qua
Pfizer beats estimates but guidance disappoints
Market Watch / Posted 9 days ago
Pfizer Inc. on Tuesday reported better-than-expected results for its fourth quarter, but offered soft guidance for 2016. Pfizer, which struck a $155 billion deal in November to combine with Allergan PLC, said it expects to earn $2.20 to $2.30 a... Read more
21 related stories
9d
Market Watch
Pfizer beats profit expectations, but provides downbeat outlookPfizer Inc. PFE, -1.05% reported on Tuesday fourth-quarter earnings of $613 mil
Pfizer beats profit expectations, but provides downbeat outlook
Market Watch / Posted 9 days ago
Pfizer Inc. PFE, -1.05% reported on Tuesday fourth-quarter earnings of $613 million, or 10 cents per share, compared with $1.228 billion, or 19 cents per share the same period a year ago. The latest results include three months of legacy Hospira... Read more
21 related stories
9d
Reuters
Pfizer revenue beats estimates, helped by pneumonia vaccine salesThe Pfizer logo is pictured on the company's World Headquarters building in the
Pfizer revenue beats estimates, helped by pneumonia vaccine sales
Reuters / Posted 9 days ago
The Pfizer logo is pictured on the company's World Headquarters building in the Manhattan borough of New York November 23, 2015. U.S. drugmaker Pfizer Inc (PFE.N), which is in the process of buying Botox-maker Allergan Plc (AGN.N) for $160 billion,... Read more
21 related stories
9d
FOX Business
Pfizer's 4Q Earnings Top EstimatesU.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan P
Pfizer's 4Q Earnings Top Estimates
FOX Business / Posted 9 days ago
U.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan Plc for $160 billion, reported better-than-expected quarterly revenue, helped by demand for its pneumonia vaccine and its Hospira acquisition. The company, however,... Read more
21 related stories
9d
FOX Business
Pfizer's 4Q Earnings Top EstimatesU.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan P
Pfizer's 4Q Earnings Top Estimates
FOX Business / Posted 9 days ago
U.S. drugmaker Pfizer, which is in the process of buying Botox-maker Allergan Plc for $160 billion, reported better-than-expected quarterly revenue, helped by demand for its pneumonia vaccine and its Hospira acquisition. Continue Reading Below The... Read more
21 related stories
10d
TheStreet.com
stop thinking so short term about biotech stocksThe stock has been declining ever since CEO Robert Hugin announced he would ste
stop thinking so short term about biotech stocks
TheStreet.com / Posted 10 days ago
The stock has been declining ever since CEO Robert Hugin announced he would step down from CEO and become executive chairman. The problem is that investors are too short-sighted, said Cramer, the co-manager of the Action Alerts PLUS portfolio.... Read more
11d
TheStreet.com
AAPL, GE, GM, YHOO: Jim Cramer's ViewsWhat will we pay for a company with flat earnings growth and a good balance she
AAPL, GE, GM, YHOO: Jim Cramer's Views
TheStreet.com / Posted 11 days ago
What will we pay for a company with flat earnings growth and a good balance sheet that also has a decent yield and can buy back a huge amount of stock and increase its dividend? What multiple can we put on a company's earnings stream where we worry... Read more
12d
Stamford Advocate
The New York Times editorial board rips apart 'brazen tax dodgers'Through a process called inversion, American companies merge with smaller compa
The New York Times editorial board rips apart 'brazen tax dodgers'
Stamford Advocate / Posted 12 days ago
Through a process called inversion, American companies merge with smaller companies located in regions where taxes are lower, like Ireland, to effectively change their "tax nationality," and pay lower rates while maintaining majority American... Read more
2 related stories
12d
Connecticut Post
The New York Times editorial board rips apart 'brazen tax dodgers'Through a process called inversion, American companies merge with smaller compa
The New York Times editorial board rips apart 'brazen tax dodgers'
Connecticut Post / Posted 12 days ago
Through a process called inversion, American companies merge with smaller companies located in regions where taxes are lower, like Ireland, to effectively change their "tax nationality," and pay lower rates while maintaining majority American... Read more
2 related stories
12d
Business Insider
The New York Times editorial board rips apart 'brazen tax dodgers'Through a process called inversion, American companies merge with smaller compa
The New York Times editorial board rips apart 'brazen tax dodgers'
Business Insider / Posted 12 days ago
Through a process called inversion, American companies merge with smaller companies located in regions where taxes are lower, like Ireland, to effectively change their "tax nationality," and pay lower rates while maintaining majority American... Read more
2 related stories
More

People in this news